(Q42756714)

English

Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.

scientific article published on 18 January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 November 2017

Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951. (English)

1 reference

Europe PubMed Central

6 November 2017

1 reference

based on heuristic

inferred from title

oligodendrocyte

1 reference

based on heuristic

inferred from title

Pieter Wesseling

7

1 reference

Europe PubMed Central

6 November 2017

object named as

Ahmed Idbaih

5

0 references

François Ducray

2

object named as

François Ducray

1 reference

Europe PubMed Central

6 November 2017

author name string

Karima Mokhtari

1

1 reference

Europe PubMed Central

6 November 2017

Johan M Kros

3

1 reference

Europe PubMed Central

6 November 2017

Thierry Gorlia

4

1 reference

Europe PubMed Central

6 November 2017

Martin Taphoorn

6

1 reference

Europe PubMed Central

6 November 2017

Khe Hoang-Xuan

8

1 reference

Europe PubMed Central

6 November 2017

Martin Van den Bent

9

1 reference

Europe PubMed Central

6 November 2017

Marc Sanson

10

1 reference

Europe PubMed Central

6 November 2017

language of work or name

0 references

publication date

18 January 2011

1 reference

Europe PubMed Central

6 November 2017

1 reference

Europe PubMed Central

6 November 2017

117

1 reference

Europe PubMed Central

6 November 2017

3014-3026

1 reference

Europe PubMed Central

6 November 2017

13

1 reference

Europe PubMed Central

6 November 2017

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

alpha-Internexin expression identifies 1p19q codeleted gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

IDH1 and IDH2 mutations in gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Monoclonal antibody specific for IDH1 R132H mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Identifiers

10.1002/CNCR.25827

1 reference

Europe PubMed Central

6 November 2017

1 reference

Europe PubMed Central

6 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42756714&oldid=1579269089"